

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)
A	WO 2011/143597 A1 (RULES BASED MEDICINE INC [US]; O'BRYANT SIDNEY E [US]; BARBER ROBERT C) 17 November 2011 (2011-11-17) * claims 1-2 * -----	1-4,9-12	INV. G01N33/68 G01N33/53
X	WO 2006/012351 A2 (UNIV WASHINGTON [US]; LADENSON JACK [US]; LANDT YVONNE [US]; MODUR VIJ) 2 February 2006 (2006-02-02) * claims 12, 16, 18, 20 * -----	1-4,9-12	
			TECHNICAL FIELDS SEARCHED (IPC)
			G01N
The supplementary search report has been based on the last set of claims valid and available at the start of the search.			
Place of search		Date of completion of the search	Examiner
Munich		8 June 2017	Hohwy, Morten
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document			

3

EPO FORM 1503 03 82 (P04N04)

### CLAIMS INCURRING FEES

The present European patent application comprised at the time of filing claims for which payment was due.

Only part of the claims have been paid within the prescribed time limit. The present European search report has been drawn up for those claims for which no payment was due and for those claims for which claims fees have been paid, namely claim(s):

No claims fees have been paid within the prescribed time limit. The present European search report has been drawn up for those claims for which no payment was due.

### LACK OF UNITY OF INVENTION

The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

see sheet B

All further search fees have been paid within the fixed time limit. The present (supplementary) European search report has been drawn up for all claims.

As all searchable claims could be searched without effort justifying an additional fee, the Search Division did not invite payment of any additional fee.

Only part of the further search fees have been paid within the fixed time limit. The present (supplementary) European search report has been drawn up for those parts of the European patent application which relate to the inventions in respect of which search fees have been paid, namely claims:

None of the further search fees have been paid within the fixed time limit. The present (supplementary) European search report has been drawn up for those parts of the European patent application which relate to the first mentioned in the claims, namely claims:

1-4, 9-12(all partially)

The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

1. claims: 1-4, 9-12(all partially)

A method for determining the risk of developing dementia in a subject by measuring one or more biomarkers in a sample from said subject, wherein the dementia is Alzheimer's disease and the one or more biomarkers comprise neuroserpin (NEUS).

---

2-67. claims: 1-15(partially)

Claims 1-15 (where applicable): A method for determining the risk of developing dementia in a subject by measuring one or more biomarkers in a sample from said subject, wherein the dementia is Alzheimer's disease and the one or more biomarkers comprise one of the 67 biomarkers of Table 2 (other than NEUS).

---

68-241. claims: 1-15(partially)

Claims 1-15 (where applicable): A method for determining the risk of developing dementia in a subject by measuring one or more biomarkers in a sample from said subject, wherein the dementia is Progressive Supernuclear Palsy (PSP) and the one or more biomarkers comprise one of the 174 biomarkers of Table 1.

---

242. claims: 1-15(partially)

Claims 1-15 (where applicable): A method for determining the risk of developing dementia in a subject by measuring one or more biomarkers in a sample from said subject, wherein the dementia is a disease different from Alzheimer's disease (AD) and Progressive Supernuclear Palsy (PSP).

---

**ANNEX TO THE EUROPEAN SEARCH REPORT  
ON EUROPEAN PATENT APPLICATION NO.**

EP 15 73 3141

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.  
The members are as contained in the European Patent Office EDP file on  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

08-06-2017

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2011143597 A1	17-11-2011	CA 2799351 A1	17-11-2011
		EP 2569451 A1	20-03-2013
		US 2014147863 A1	29-05-2014
		WO 2011143597 A1	17-11-2011
-----			
WO 2006012351 A2	02-02-2006	CA 2571445 A1	02-02-2006
		CA 2891635 A1	02-02-2006
		EP 1774023 A2	18-04-2007
		EP 2514837 A1	24-10-2012
		ES 2428795 T3	11-11-2013
		JP 5190261 B2	24-04-2013
		JP 2008504032 A	14-02-2008
		US 2008131881 A1	05-06-2008
		US 2012021534 A1	26-01-2012
WO 2006012351 A2	02-02-2006		
-----			

专利名称(译)	痴呆和痴呆相关神经系统疾病的生物标志物		
公开(公告)号	<a href="#">EP3092494A4</a>	公开(公告)日	2017-10-18
申请号	EP2015733141	申请日	2015-01-06
[标]申请(专利权)人(译)	儿童医学中心公司		
申请(专利权)人(译)	儿童医学中心CORPORATION		
当前申请(专利权)人(译)	儿童医学中心CORPORATION		
[标]发明人	BARNABY OMAR S STEEN JUDITH AJ STEVENS BETH STEEN HANNO HONG SOYON Y		
发明人	BARNABY, OMAR S. STEEN, JUDITH AJ STEVENS, BETH STEEN, HANNO HONG, SOYON Y.		
IPC分类号	G01N33/68 G01N33/53		
CPC分类号	C12Q2600/118 C12Q2600/158 G01N33/6896 G01N2800/2814 G01N2800/2821 G01N2800/50 G01N2800/60		
优先权	61/923995 2014-01-06 US		
其他公开文献	EP3092494A1		
外部链接	<a href="#">Espacenet</a>		

### 摘要(译)

本发明提供基于CSF蛋白的生物标志物和生物标志物组合，其可用于诊断患者的痴呆或痴呆相关的神经障碍。特别地，本发明的生物标志物可用于将受试者样品分类为阿尔茨海默氏痴呆，非阿尔茨海默氏痴呆，进行性核上性麻痹 (PSP)，非PSP痴呆或正常。在一些方面，本发明涉及用于诊断，分类和分析患者的痴呆或痴呆相关神经障碍的方法。

DOCUMENTS CONSIDERED TO BE RELEVANT			Relevant to claim?	CLASSIFICATION OF THE APPLICATION (IPC)
Category	Classifications of documents with a citation, where appropriate, of relevant passages	Date of publication		
A	WO 2011/143597 A1 (EMULE BASED MEDICINE INC [US]; O'BRYAN SIDNEY E [US]; BARBER ROBERT G) 17 November 2011 (2011-11-17) * claims 1-2	1-4-9-12		B01 G01N33/68 G01N33/53
X	WO 2006/012351 A2 (UNIV WASHINGTON [US]; LABERGEON JACK [US]; LANDT VYONNE [US]; MODUR VIJ) 2 February 2006 (2006-02-02) * claims 15, 16, 18, 20	1-4-9-12		

The supplementary search report has been based on the last set of claims valid and available at the start of the search.

3  
Munich 8 June 2017 Hohwy, Morten

CLASSIFICATION OF CITED DOCUMENTS

1: priority of foreign application; the invention is not disclosed in the prior art of the country of origin of the application; 2: document cited for comparative purposes; 3: document cited for other reasons; 4: document of the same patent family, corresponding document